

Newsletter #14

07 March 2022

Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration

Total number of cases reported

128

Countries (n = 14) that assessed children, n

Argentina	2	Mexico	2	Russia	6
France	68	Netherland	1	Sweden	1
Greece	1	Poland	13	Turkey	5
India	6	Portugal	3	United Kingdom	5
Italy	12	Romania	3		

Children

Girls / boys	61 / 63
Age (mean ± SD)	12.4 ± 3.7 y

Psoriasis before COVID-19

Age of onset of psoriasis (mean ± SD)	7.1 ± 4.0 y
Plaque psoriasis	82
Nail psoriasis	52
Psoriasis arthritis	7

COVID-19

Confirmed / suspected	114 / 14
N° of COVID-19 / child	
1	120
2	4
Symptoms, yes	81
Hospitalization	6
Long-Covid	2

Since COVID-19 onset, the psoriasis has

Improved	1
Worsened, with same psoriasis phenotype	18
Worsened, phenotype changed	1
Remained same	92
Psoriasis de novo	8
No information	8

Systemic medication for psoriasis at time of onset of COVID-19

Phototherapy	6	Adalimumab	14
Methotrexate	16	Etanercept	4
Acitretin	8	Ustekinumab	16
Cyclosporine	1	Risankizumab	1
Apremilast	1	Secukinumab	1

You can include children with psoriasis and COVID-19 on:

<https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfnx4ky8CEUILWa7veJmHb0FthGKuudaQDwbCfNQ/viewform?vc=0&c=0&w=1&flr=0>

<https://www.sfdermato.org/groupe-46-chi-psocov>